spacer
home > ebr > autumn 2017 > definitive screening designs
PUBLICATIONS
European Biopharmaceutical Review

Definitive Screening Designs

The ability to quickly develop reliable and robust analytical test methods is an important aspect of navigating the technical path to a successful investigational new drug (IND) submission. Often, an insufficient amount of time is allocated to understanding analytical methods and reference materials and how they perform at in-process test points.

Charge Heterogeneity

Analytical comprehension is particularly challenging for proteins expressed in mammalian cells, which can present extensive charge heterogeneity resulting from variations in post-translational modifications (PTMs). The milieu parameters in any given bioprocess can impact charge heterogeneity, which, when not properly understood and controlled, can cause unwanted batch-to-batch variation in product quality.

Therefore, early detection of charge heterogeneity, using a robust method with good resolution, is an important capability for process development. Some PTMs result in charge differences on the molecule that are likely to alter the protein’s stability or activity.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Srividya Suryanarayana has over five years’ industry experience at Cytovance Biologics and over seven years’ academic experience in R&D. She is a subject matter expert on charge-based analytical methods using icIEF and has a strong background in enzymology, protein biochemistry, analytical method development, qualification and validation. Srividya is a method validation lead scientist in Quality Control at Cytovance Biologics, leading method validation activities for several client-specific projects. She holds a PhD in biochemistry/biophysics from the University of Kansas, US, and has completed post-doctoral training from the Medical College of Wisconsin, US.
spacer
Dr Srividya Suryanarayana
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

TAGRISSOTM (osimertinib) DEMONSTRATED UNPRECEDENTED DISEASE-FREE SURVIVAL IN THE ADJUVANT TREATMENT OF STAGE IB-IIIA COMPLETELY RESECTED PATIENTS WITH EGFR MUTATION

Detailed results from the Phase III ADAURA trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection with curative intent.
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement